Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.86 -0.07 (-0.54%)
Streaming Delayed Price Updated: 12:45 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗
Via Chartmill
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗
Via Chartmill
News headline image
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗
Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the... 
Via MarketBeat
News headline image
Amylyx (AMLX) Q1 2026 Earnings Transcript ↗
Amylyx (AMLX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗
Amylyx (AMLX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million ↗
A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
Via The Motley Fool
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.